The effects of multi-tasking upon stress reactivity: an acute, double-blind, placebo controlled crossover study of 320mg and 640mg doses of Bacopa monnieri (CDRI08).
The Ayurvedic medicine, Bacopa monnieri (L.) Wettst. (syn. Bacopa monniera) has been used for thousands of years to treat a wide variety of mental ailments (Russo and Borrelli 2005) . Recently, standardized extracts of Bacopa monnieri (BM) have been developed and have been subjected to randomised placebo controlled trials to evaluate the reported cognitive enhancing properties of the herb . Growing evidence suggests that standardised extracts of BM do promote cognitive enhancement in older (>54 years) cohorts (Barbhaiya et al. 2008; Calabrese et al. 2008; Morgan and Stevens 2010) and healthy adults (18-60 years) over chronic (3-4 months) administration periods (Stough et al. 2008; Stough et al. 2001a) . In addition to these cognitive enhancing properties, BM has also been reported to possess anxiolytic, antidepressant, sedative, and adaptogenic actions (Russo and Borrelli 2005) which may co-occur with or facilitate the reported cognitive enhancement associated with BM consumption.
Preclinical work originally established BM potential as a cognitive enhancer and mood modulator with in vivo and in vitro studies indicating BM has adaptogenic (Rai et al. 2003) , antioxidant (Shinomol et al. 2011) , cholinergic (Uabundit et al. 2010) , metal chelating (Dhanasekaran et al. 2007) , vasorelaxant (Dar and Channa 1999) and anti-inflammatory properties (Channa et al. 2006 ). Emergent evidence from animal studies suggests that BM may acutely improve cognition, particularly when participants are engaged in cognitively challenging or stressful paradigms (Andrade and Chandra 2006b; Saraf et al. 2008) . BM has been observed to improve or restore learning and memory within a wide range of animal paradigms including scopolamine, electroshock and immobilization stress induced retrograde amnesia models (Singh and Dhawan 1997) . BM supplementation has also produced neuroprotection and restoration of cognitive performance in animal models of induced cognitive deficits by N  -nitro-L-arginine (Anand et al. 2010; Saraf et al. 2009 ), diazepam Saraf et al. 2008) , hypobaric hypoxia (Hota et al. 2009 ), and electroconvulsive shock (Andrade and Chandra 2006a) . These types of animal models also increase anxiety-like behavior and stress related biological indices in animals. For instance the scopolamine and intermittent hypoxia models have been reported to produce anxious behaviour in rodents (Duarte et al. 2010; Klinkenberg and Blokland 2010) , and increase production of stress hormones such as corticosterone (Zoccal et al. 2007 ). Given BM treatment has also been reported to reduce anxiety in mice (Russo and Borrelli 2005) and illustrated adaptogenic (Rai et al. 2003) and corticosterone reducing properties in rat models (Sheikh et al. 2007 ), these anxiogenic and stress moderating effects need to be considered as possible mediators of the treatment related effects of BM in both pre-clinical and future human trials.
The steroidal saponins, Bacoside A and Bacoside B (Deepak and Amit 2004) are considered to be the primary psychoactive constituents of BM and have various mechanisms of action upon the central nervous system including antioxidant activity (Dhanasekaran et al. 2007; Russo and Borrelli 2005) and enhancement of kinase activity, restoration of synaptic activity and ultimately nerve impulse transmission (Anbarasi et al. 2005; Rai et al. 2003; Saraf et al. 2008) . Of specific relevance to this study are the anxiolytic and adaptogenic properties of BM, given the potential relationship between these effects inferred from pre-clinical studies demonstrating acute improvement in cognitive performance under laboratory induced stressful conditions (Andrade and Chandra 2006b; Saraf et al. 2008 ).
To date, limited research exists concerning the acute effects of BM consumption with humans. The first study to assess the potential of an acute nootropic effect of BM in humans, observed no acute effect on cognitive performance two hours post treatment consumption (Nathan et al. 2001) . No assessment of mood, anxiety or any biological measures related to the possible adaptogenic properties of BM were collected from the participants limiting any speculation concerning whether BM (at the dose administered) produced any anxiolytic effect independent of the lack of nootropic effect. Recently, a second study (Downey et al. 2012) examined the acute effect (again, at 2 hours post-treatment) of two doses (320mg and 640mg) of a specific extract of BM (KeenMind ® : CDRI 08) upon performance on a series of mentally effortful cognitive tasks, cardiovascular parameters, and mood. Change from baseline scores indicated that the 320mg dose of BM improved performance at the 1 st , 2 nd , and 4 th repetition (coinciding with 120 -160 min) post-dosing of a mentally effortful cognitive battery.
Although no treatment effect was observed upon cardiovascular activity or in attenuating task induced ratings of stress and fatigue. It was concluded that assessment of an earlier pharmacological window may be appropriate given the nootropic effect was evident in the earlier cognitive assessments. This finding is consistent with extant research that has demonstrated that chronic consumption of standardized extracts of BM can improve components of human cognition (Calabrese et al. 2008; Morgan and Stevens 2010; Stough et al. 2008; Stough et al. 2001a; Stough et al. 2012 ) including speed of information processing, decision-making time (Stough et al. 2008; Stough et al. 2001a) , and aspects of attention/freedom of distractibility (Barbhaiya et al. 2008; Calabrese et al. 2008 ) after chronic supplementation.
In addition to the cognitive enhancement detected in chronic supplementation studies, reductions in trait anxiety as a result of chronic BM supplementation have also been observed (Calabrese et al. 2008; Stough et al. 2001a) . Whilst an anxiolytic finding has not been observed or assessed consistently in chronic supplementation studies, evidence from preclinical studies support the notion that BM possesses anxiolytic and adaptogenic properties and that these properties may be more evident in stressful or cognitively challenging paradigms (Andrade and Chandra 2006b; Saraf et al. 2008) . Biological assessment of BM treatment related and task induced modulation of mood in acute settings has only been recently undertaken in humans, with BM treatment having no effect upon cardiovascular activity 2 h post-treatment (Downey et al. 2012) . Given the wide-ranging biological effects of BM observed in pre-clinical studies (Russo and Borrelli 2005) , the pharmacological window used, and possible insensitivity of the cardiovascular assessments used in a relatively young and healthy population, the lack of a detectable change in cardiovascular functioning specific to BM consumption is not surprising.
Studies utilizing cross-over designs have previously assessed modulation of cognitive performance, stress reactivity (assessed via saliva cortisol levels and self-rated affective state), and mood by purportedly nootropic, anxiolytic and adaptogenic substances (Hellhammer et al. 2004; Kennedy et al. 2006a; Kennedy et al. 2006b; McMorris et al. 2006; Scholey et al. 2009 ). For example, the effects of controlled administration of phosphatidylserine complex has been shown to attenuate the cortisol response to laboratory induced stress (using the Trier Social Stressor Test), particularly with a 400mg dose, and also produced positive self-rated emotional response to the same treatment (Hellhammer et al. 2004) . Similarly, using a computerized Multitasking Framework designed to evoke stress and additionally collect cognitive performance metrics, the effect of chewing gum on alleviating stress and negative mood associated with completion of the stressful cognitive task battery has recently been examined (Scholey et al. 2009 ). Chewing gum throughout completion of the Multitasking Framework was associated with significant improvements in levels of alertness and cognitive task performance and reductions in state anxiety, stress and levels of salivary cortisol. The efficacy of the phosphatidylserine was attributed to a selective stress dampening effect on the pituitary-adrenal axis (Hellhammer et al. 2004) , and although the mechanism by which chewing gum was efficacious in alleviating task induced stress and cortisol production is less clear, the ability to experimentally induce the stress-cortisol response and collect mood and cognitive data concurrently provides an ideal platform to assess the acute effects of various doses of interventions such as BM.
The above evidence suggests the effects of nootropics on responses to stress can be dissociated from their effect upon behavior. Given the established evidence of a facilitative cognitive and anxiolytic effect due to chronic BM consumption in humans, and preclinical evidence for cognitive, adaptogenic and anxiolytic effects within acutely stressful paradigms, the aim of the current study was to ascertain whether a standard clinical dose of 320mg or a 640mg dose of a specific extract of BM (KeenMind ® -CDRI 08) would acutely effect cognition, mood, anxiety and stress at an earlier time-point than previous acute BM supplementation studies. The present study therefore aimed to test the hypotheses that compared to a placebo, BM would attenuate task induced negative mood change, result in reduced cortisol levels, and improve cognitive task performance. Mental Arithmetic: This task requires participants to add a series of numbers. Using a number pad on the computer screen, participants used the computer mouse to click the numbers that gave the desired answer. Participants were awarded 10 points for a correct answer or deducted 10 points for an incorrect answer.
Method
Stroop: A series of colour names (red, blue, yellow and green) were presented in differing font colours (red, blue, yellow and green) and the participants were required to respond to the colour of the font by using their computer mouse to click on one of the four available answers. Participants were awarded 10 points for a correct answer or deducted 10 points for an incorrect answer and for not selecting a response within the allocated time frame.
Letter Search: Four letters were presented during the initial four seconds of testing. The letters then disappeared, but could be reviewed at any time by clicking on a "retrieve list"
button. At 10-second intervals a single target letter appeared and the participant indicated whether or not the letter belonged to the original four letters by clicking on a "yes" or a "no"
button. Participants were awarded 10 points for a correct answer, deducted 10 points for an incorrect answer or no response and deducted five points for each time they retrieved the letter list.
Visual Tracking: A dot progressively moved outwards from the centre of the task through five concentric circles. Participants were asked to allow the dot to travel as far from the centre as possible without letting it touch the edge of the outermost circle before clicking on a "reset" button. Two points were awarded per circle that the dot had passed through, with a maximum of 10 points. Participants were deducted 10 points per half second that the dot touched the outer edge before resetting the task. The Multitasking Framework has been shown to increase negative mood and anxiety (Scholey et al. 2009 ) and induce a stressrelated physiological response (Wetherell and Sidgreaves 2005) .
Mood Measures
The Bond-Lader VAS (Bond and Lader 1974) and the State Trait Anxiety Inventory (STAI; (Spielberger et al. 1970 ) were used to evaluate mood. The Bond-Lader VAS consists of 16 visual analogue scales with the end points anchored by antonyms reflecting three key mood factors: "alert" (alert-drowsy, attentive-dreamy, lethargic-energetic, muzzy-clearheaded, coordinated-clumsy, mentally slow-quick witted, strong-feeble, interested-bored, incompetent-proficient), "calm" (calm-excited, tense-relaxed) and "content" (contenteddiscontented, troubled-tranquil, happy-sad, antagonistic-friendly, withdrawn-sociable).
Scores for each item represent the number of millimeters, ranging from 0 to 100, from the negative antonym. Item scores were summed and averaged to create total scores for each respective factor. Factor scores had a potential range between 0 and 100, with 100 representing highly alert, calm or content. A pen and paper version was used and participants were asked to mark each line between the antonyms indicating how they felt at the present time. As with many mood visual analogue scales, high reliability and validity have been demonstrated (Ahearn 1997 ).
The state anxiety subscale (STAI-S) of the State Trait Anxiety Inventory (Spielberger et al. 1970 ) was utilised to assess participants' state level anxiety before and after completion of the Multitasking Framework. The STAI-S consists of 20 items measured on a four-point Likert scale with 1= 'not at all' and 4 = 'very much so'. After reversing certain items as appropriate, the scores were summed to give the overall score, higher scores reflected greater state anxiety. The trait anxiety subscale (STAI-T) of the State Trait Anxiety Inventory (Spielberger et al. 1970 ) was utilised in the practice session to assess participants' trait anxiety level. The STAI-T consists of 20 items on a four-point Likert scale with 1= 'almost never' and 4 = 'almost always', with higher scores reflecting greater levels of trait anxiety.
Biological Measure
The participants provided salivary samples using salivettes (Sarstedt, UK) as a non-invasive measure of free, bio-available cortisol levels. Participants were required to place a cotton dental roll in their mouth for approximately 30 s, these were immediately frozen at − 20 °C.
Samples were defrosted and centrifuged prior to testing for cortisol levels by luminescence immunoassay according to the instructions of the manufacturers (IBL Hamburg, Flughafenstrasse 52a, D-22335 Hamburg, Germany).
Procedure
Each participant was required to attend a total of four sessions (one practice visit and three study visits) that were conducted one week apart to ensure sufficient wash out between each acute condition. Participants were asked to consume a light breakfast (e.g., one standard serve of cereal or two pieces of toast at home on each testing day) before arriving at the testing was carried out in all three study visits.
Data treatment and statistics
To examine the first aim of the current study, the effects of condition and time on
Multitasking Framework task performance and to investigate the hypothesis that the 320 mg Bacopa monniera condition would not have a significant enhancing effect on cognition; the analysis was carried out using change scores. These scores were calculated by finding the change from the pre-dose baseline to the one and two-hour post-dose testing sessions for each task and the total Multitasking Framework score (e.g., one hour post-treatment Stroop score minus the baseline Stroop score). Two-way repeated-measures ANOVAs employing condition (placebo, 320 mg, and 640 mg) and time (change score for baseline to 1h, change score for baseline to 2 h) were conducted for the total Multitasking Framework score and for Maths, Stroop, Letter search and tracking scores. Post-hoc comparisons using paired-samples t-tests were conducted for further analyses where appropriate. To establish the effects of condition and time on mood, state anxiety, and stress, analyses were run in the absence and in the presence of the stressor. In order to establish the effects in the absence of the stressor, the change from the baseline scores to the one hour and two hours post-treatment pre-stressor scores were calculated. A series of 2-way repeated measures ANOVA with condition (placebo, 320mg, 640mg) and time (baseline to 1 h change, baseline to 2 h change) were employed. Further analyses were performed using paired-samples t-tests.
To determine the effects of the conditions on the stress related change in the mood, anxiety and cortisol measurements caused by the Multitasking Framework, a change score was calculated for each of the variables at each session time by subtracting the post Multitasking
Framework score from the pre Multitasking Framework score. The change from baseline scores at one and two hours post-dosage were then calculated by subtracting the pre-dose change from the one hour and the two hours post-dosage change scores. These delta scores were analysed for each factor by employing a two-way repeated measures ANOVA incorporating factors of Time (1 h, 2 h) x Condition (placebo, 320 mg, 640 mg).
Results
No adverse effects were reported throughout the study for any of the three treatments. Prior to examination of the cortisol, mood and cognitive testing results, all data were examined with regard to gender and treatment order effects, with no significant pattern of results emerging.
Baseline performance scores (mean and standard error) for the Multitasking Framework and difference from baseline scores for each outcome measure and treatment are summarized in Increased levels of Contentedness were identified in the 640mg condition after completion of the Multitasking Framework at the one hour post-dosing testing time-point. The 640mg BM condition also produced significantly lower cortisol levels (greater reduction from baseline)
at the one and two hour post-dosing time-points prior to completion of the multi-tasking cognitive battery. No significant differences between conditions were identified in cortisol reactivity following completion of the Multitasking Framework, possibly indicating that at the doses assessed and the timeline of the cortisol assessments that the BM had no obvious acute effect upon attenuation of cortisol production.
Consumption of the clinically standard dose of BM (320mg; CDRI08) improved Letter
Search and Stroop task performance (1 and 2-hrs post-dosing) and Alertness ratings (2 h) prior to completion of the Multitasking Framework. This improvement in Stroop task performance is consistent with faster information processing and decision-making time (Stough et al. 2008; Stough et al. 2001a) , and improvement in aspects of attention/freedom of distractibility (Barbhaiya et al. 2008; Calabrese et al. 2008 ) previously noted in chronic BM supplementation studies.. Improvement in the Letter Search task is more consistent with the memory enhancing qualities of BM reported in chronic intervention studies (Barbhaiya et al. 2008; Calabrese et al. 2008; Morgan and Stevens 2010; Stough et al. 2008; Stough et al. 2001a ), that have not been previously demonstrated in the only previously published acute BM supplementation study (Nathan et al. 2001) .
That some degree of cognitive enhancement was evident at both the one and two hour post BM administration suggests that the previously investigated neuropsychological tests were insensitive to the acute nootropic effects of BM within the pharmacological window that was employed (Nathan et al. 2001) . Aspects of the tests employed may have precluded detection of any nootropic effect attributable to BM given tests such as the Rey Auditory Verbal Learning Test and Digit Span are not administered under any time pressure, and faster responding does not increase performance scores. The improved performance in these cognitive tests may have been elicited by improvement in aspects of cognition that are more relevant to multi-tasking on time-sensitive cognitive tasks including cognitive speed and reasoning . Changes in these abilities may also account for the memory enhancing effects attributed to BM in previous chronic dosing studies given these aspects of cognition would be involved in completion of the range of memory-specific cognitive tasks employed to assess the nootropic effects of BM (Calabrese et al. 2008; Mandal et al. 2011; Stough et al. 2008; Stough et al. 2001a) . Future acute and chronic administration studies of BM could therefore aim to dissociate aspects of cognitive performance relevant to tests of memory and attention to identify the possible mechanism for improved cognitive performance attributable to BM (Downey et al. 2012) .
Acute improvement in cognitive performance elicited by BM could be attributed to the purported adaptogenic and anxiolytic properties of BM that may have been evinced in the cognitively challenging paradigm utilized in the current study. In regards to the subjective outcomes, ratings of Alertness (2 h post dosing with 320mg BM) and Contentedness (1 h post dosing with 640mg BM) were observed to be improved. Whilst the ratings of mood and state anxiety were not observed to consistently improve in the absence of completion of the Multitasking Framework, or attenuate any task induced mood modulation, examination of the means reveal that the placebo condition was generally more negatively affected by completion of the multiple cognitive assessments than the two BM conditions. This suggests that at the doses administered, the subjective effect of any anxiolytic or antidepressant action may be subtle, or obscured by task completion. Limited evidence from human studies exist for any positive mood moderating action of BM (Calabrese et al. 2008; Stough et al. 2001b) , although this effect has not been evident in all chronic supplementation studies (Roodenrys et al. 2002; Stough et al. 2008) , and was not assessed in the previous acute supplementation study (Nathan et al. 2001) . The current results suggest that at the doses assessed, BM does not fully attenuate the experience of experimentally induced mood deficits after two completions of multitasking assessments, but did have some positive effect upon mood at each testing time-point that may have facilitated the positive cognitive performance findings.
Given the small sample size, imbalance of genders, and the relatively small change from baseline average scores in the subjective mood ratings, it would be important to replicate this finding of selective mood enhancement in a larger sample, and in the absence of cognitively demanding tasks to quantify the magnitude of the subjective effects.
Assessment of the effect of BM upon cortisol reactivity was undertaken pre-and postcompletion of the Multitasking Framework to assess any physiological adaptogenic effect of BM consumption. The treatment related effects were strongest in the 640mg BM condition, where at both one and two hours post-treatment, the change from baseline scores for saliva cortisol were larger in comparison to both the 320mg and placebo conditions. This is somewhat consistent with the adaptogenic properties inferred from pre-clinical studies for BM where acute improvement in cognitive performance has been observed under laboratory induced stressful conditions (Andrade and Chandra 2006b; Saraf et al. 2008) . Interestingly, following completion of the Multitasking Framework at each time-point, no significant differences in levels of cortisol were evident between treatments, suggesting the adaptogenic effect of BM was limited to reducing cortisol between assessments, rather than attenuating the response due to the completion of the multitasking. This pattern of results is similar to the findings of Sheikh and colleagues who, in models of acute and chronic unpredictable stress, observed changes in plasma corticosterone, noradrenaline, serotonin and dopamine in the cortex and hippocampal regions of rat brains (Sheikh et al. 2007) . They noted that the adaptogenic properties of BM manifested via normalization of stress induced changes in corticosterone and monoamine levels in the cortex and hippocampus when applied as a pretreatment to exposure to stressful conditions (Sheikh et al. 2007 ).
The current study examined the effect of two doses of BM for possible cognitive-enhancing, adaptogenic and anxiolytic effects on the basis of growing preclinical and human trial evidence for BM related nootropic efficacy within acutely stressful paradigms. We observed some positive cognitive effects, notably at both one hour post BM consumption suggesting an earlier nootropic effect of BM than previously investigated, and two hours post BM consumption on tasks more dependent upon aspects of reasoning and cognitive speed than the previously investigated tests of memory (Nathan et al. 2001) . Subjective ratings of mood and anxiety were not consistently affected by BM consumption (although Alertness and Contentedness ratings were increased), with any anxiolytic or mood enhancing qualities of Table 5 : Mean (±SD) change scores for anxiety ratings for the three treatment conditions preand post-dosing and pre-and post-MTF completion
